Vogt A - Search Results

1

A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing.

Vogt A, Qian Y, Blaskovich MA, Fossum RD, Hamilton AD, Sebti SM. Vogt A, et al. J Biol Chem. 1995 Jan 13;270(2):660-4. doi: 10.1074/jbc.270.2.660. J Biol Chem. 1995. PMID: 7822292 Free article.

2

Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors.

Kauffmann RC, Qian Y, Vogt A, Sebti SM, Hamilton AD, Carthew RW. Kauffmann RC, et al. Among authors: vogt a. Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10919-23. doi: 10.1073/pnas.92.24.10919. Proc Natl Acad Sci U S A. 1995. PMID: 7479910 Free PMC article.

3

Burkitt lymphoma Daudi cells contain two distinct farnesyltransferases with different divalent cation requirements.

Vogt A, Sun J, Qian Y, Tan-Chiu E, Hamilton AD, Sebti SM. Vogt A, et al. Biochemistry. 1995 Sep 26;34(38):12398-403. doi: 10.1021/bi00038a037. Biochemistry. 1995. PMID: 7547984

4

Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.

Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD, Sebti SM. Lerner EC, et al. Among authors: vogt a. J Biol Chem. 1995 Nov 10;270(45):26802-6. doi: 10.1074/jbc.270.45.26802. J Biol Chem. 1995. PMID: 7592920 Free article.

5

CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase.

McGuire TF, Qian Y, Blaskovich MA, Fossum RD, Sun J, Marlowe T, Corey SJ, Wathen SP, Vogt A, Hamilton AD, et al. McGuire TF, et al. Among authors: vogt a. Biochem Biophys Res Commun. 1995 Sep 5;214(1):295-303. doi: 10.1006/bbrc.1995.2287. Biochem Biophys Res Commun. 1995. PMID: 7669049

6

Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.

Qian Y, Vogt A, Sebti SM, Hamilton AD. Qian Y, et al. Among authors: vogt a. J Med Chem. 1996 Jan 5;39(1):217-23. doi: 10.1021/jm950414g. J Med Chem. 1996. PMID: 8568811

7

Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation.

McGuire TF, Qian Y, Vogt A, Hamilton AD, Sebti SM. McGuire TF, et al. Among authors: vogt a. J Biol Chem. 1996 Nov 1;271(44):27402-7. doi: 10.1074/jbc.271.44.27402. J Biol Chem. 1996. PMID: 8910319 Free article.

8

Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts.

Vogt A, Qian Y, McGuire TF, Hamilton AD, Sebti SM. Vogt A, et al. Oncogene. 1996 Nov 7;13(9):1991-9. Oncogene. 1996. PMID: 8934546

9

The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner.

Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM. Vogt A, et al. J Biol Chem. 1997 Oct 24;272(43):27224-9. doi: 10.1074/jbc.272.43.27224. J Biol Chem. 1997. PMID: 9341167 Free article.

10

Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics.

Qian Y, Vogt A, Vasudevan A, Sebti SM, Hamilton AD. Qian Y, et al. Among authors: vogt a. Bioorg Med Chem. 1998 Mar;6(3):293-9. doi: 10.1016/s0968-0896(97)10040-2. Bioorg Med Chem. 1998. PMID: 9568283

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,052 results

Search Page

Filters